Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Targeted regulation of self-peptide presentation prevents type I diabetes in mice without disrupting general immunocompetence
Woelsung Yi, … , Derek B. Sant’Angelo, Lisa K. Denzin
Woelsung Yi, … , Derek B. Sant’Angelo, Lisa K. Denzin
Published March 1, 2010
Citation Information: J Clin Invest. 2010;120(4):1324-1336. https://doi.org/10.1172/JCI40220.
View: Text | PDF
Research Article Immunology

Targeted regulation of self-peptide presentation prevents type I diabetes in mice without disrupting general immunocompetence

  • Text
  • PDF
Abstract

Peptide loading of MHC class II (MHCII) molecules is directly catalyzed by the MHCII-like molecule HLA-DM (DM). Another MHCII-like molecule, HLA-DO (DO), associates with DM, thereby modulating DM function. The biological role of DO-mediated regulation of DM activity in vivo remains unknown; however, it has been postulated that DO expression dampens presentation of self antigens, thereby preventing inappropriate T cell activation that ultimately leads to autoimmunity. To test the idea that DO modulation of the MHCII self-peptide repertoire mediates self tolerance, we generated NOD mice that constitutively overexpressed DO in DCs (referred to herein as NOD.DO mice). NOD mice are a mouse model for type 1 diabetes, an autoimmune disease mediated by the destruction of insulin-secreting pancreatic β cells. Our studies showed that diabetes development was completely blocked in NOD.DO mice. Similar to NOD mice, NOD.DO animals selected a diabetogenic T cell repertoire, and the numbers and function of Tregs were normal. Indeed, immune system function in NOD.DO mice was equivalent to that in NOD mice. NOD.DO DCs, however, presented an altered MHCII-bound self-peptide repertoire, thereby preventing the activation of diabetogenic T cells and subsequent diabetes development. These studies show that DO expression can shape the overall MHCII self-peptide repertoire to promote T cell tolerance.

Authors

Woelsung Yi, Nilufer P. Seth, Tom Martillotti, Kai W. Wucherpfennig, Derek B. Sant’Angelo, Lisa K. Denzin

×

Figure 4

Selection and function of BDC2.5 T cells and BDC2.5-like T cells is unperturbed in NOD.DO mice.

Options: View larger image (or click on image) Download as PowerPoint
Selection and function of BDC2.5 T cells and BDC2.5-like T cells is unpe...
(A) PLN cells pooled from 5- to 7-week-old NOD and NOD.DO mice were stained with PE-labeled I-Ag7/CLIP or I-Ag7/BDC13 tetramers and APC-labeled anti-CD4 and tetramer-positive cells were enriched with anti-PE microbeads. Plots show tetramer versus CD4 after gating for CD3+CD4+B220–CD8–. Percentages on top of gates are percentages of CD4+tetramer+ cells and numbers to the left are absolute numbers of CD4+tetramer+ cells. These numbers were derived after analyzing 40% of the PLN lymphocytes pooled from 5 NOD or NOD.DO mice. Therefore, each mouse had approximately 70 BDC2.5-like T cells in its PLN. Data are representative of 3 independent experiments. (B) FACs analysis of thymocytes (top) and splenocytes (bottom) from BDC2.5/NOD and BDC2.5/NOD.DO mice. Numbers in quadrants indicate percentage of total cells falling within each gate. Data are representative of 4 to 5 total mice/genotype analyzed in 2 independent experiments. (C) BDC2.5 TCR Tg T cells from NOD.DO mice proliferate in response to Ag in vivo. CFSE-labeled BDC2.5 T cells from NOD or NOD.DO mice were transferred into NOD recipients, and 3 days later, CFSE dilution was monitored for the CD4+Vβ4+ T cells in pancreatic and inguinal LNs of recipient mice. Numbers next to gates are the percentage of total CFSE+CD4+Vβ4+ cells that underwent at least one round of proliferation. (D) Quantification of data in C for multiple mice. Each symbol represents an individual mouse, and small horizontal bars indicate the mean. One of 2 independent experiments is shown.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts